As the founder and board chairman of Emergent BioSolutions of Rockville, Maryland, Fuad El-Hibri leads a company which develops and distributes vaccines for infectious diseases. Fuad El-Hibri shares his knowledge as a member of the board of directors of the International Biomedical Research Alliance.
The Alliance is a combined effort of the U.S. National Institute of Health (NIH) and laboratories of Oxford and Cambridge Universities in the United Kingdom. Its purpose is to supplement governmental support of these organizations.
The Alliance’s Scholars Program promotes accelerated progress in the academic careers of MD and PhD students, who are expected to complete their studies in four years. Participants build collaborations between labs at NIH and Oxford or Cambridge.
Scholars work in interdisciplinary teams, not only within biomedicine but other fields, such as physics, mathematics, and other physical sciences. This approach creates a culture revolving around the free flow of information from various sources.
Since its formation in 2005, the Alliance has become the world’s most selective organization of biomedical inquiry. Scholars’ GPAs have averaged between 3.8 and 3.9. They have published a total of 417 journal articles, 153 of which represent lead author credits.
